EndoShunt

Cover Block

PUBLIC

Name	EndoShunt
Tagline	Developing a targeted endovascular shunt for rapid control of abdominal hemorrhage in trauma surgery.
Headquarters	Cambridge, MA
Founded	2021
Stage	Pre-Seed
Business Model	B2B
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Pre-seed
Total Disclosed	~$75,000 [CompanyCheck]

Links

PUBLIC

• Website: https://www.endoshunt.com
• LinkedIn: https://www.linkedin.com/company/endoshunt

Executive Summary

PUBLIC

EndoShunt is developing a temporary, endovascular shunt designed to give trauma surgeons more time to save lives by rapidly controlling abdominal hemorrhage while preserving blood flow to the rest of the body [Harvard Innovation Labs]. The company's focus on a specific, high-mortality surgical problem, combined with a path to FDA 510(k) clearance, makes it a candidate for investors looking at early-stage, hardware-driven medical interventions with a clear clinical rationale. Founded in 2021 by a team that includes a Harvard Biodesign Lab PhD candidate and a practicing trauma surgeon, the company is currently navigating its pre-commercial phase with support from academic incubators and non-dilutive grant funding [Harvard GRID, Feb 2024] [CompanyCheck].

The core product is a length-adjustable shunt intended for placement in major abdominal vessels, aiming to address the limitations of traditional clamping, which can cause ischemic injury [Perplexity Sonar Pro Brief]. While the device is still in development, the company reports it has secured support from seven hospitals for a targeted launch following regulatory clearance, though these institutions are not publicly named [Harvard GRID, Feb 2024]. Funding to date appears limited, with one secondary source reporting a total of $75,000 raised in a strategic round, though the company is also a recipient of an NIH SBIR grant [CompanyCheck] [SBIR.gov]. The critical milestones for the next 12-18 months are the completion of its ongoing Series A fundraising effort and the submission of its device for FDA review, which will test both its clinical validation and its ability to execute on a capital-intensive regulatory pathway.

Data Accuracy: YELLOW -- Product description and founder role corroborated by Harvard sources; funding figure from a single commercial database; hospital support claims are company-sourced.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Pre-seed (total disclosed ~$75,000)

Company Overview

PUBLIC

EndoShunt Medical Inc. was founded in 2021 as a hardware-focused medical device startup, with its operational base in Cambridge, Massachusetts [Crunchbase]. The founding narrative centers on developing a targeted solution for a persistent problem in emergency trauma surgery, originating from work at the Harvard Biodesign Lab [Harvard GRID, Feb 2024]. The company’s early trajectory shows a pattern of academic and incubator support, beginning with participation in the Harvard Innovation Labs and later the Wond’ry Launch incubator and Science Inc. accelerator [Harvard Innovation Labs] [CB Insights, Feb 2024].

Key operational milestones follow a medtech development path. The company secured a pre-seed round in November 2022, though the amount and lead investor remain undisclosed [Crunchbase, Nov 2022]. A non-dilutive NIH SBIR grant provided early-stage validation and funding [SBIR.gov]. Public data indicates a strategic funding round totaling $75,000, though the timing is unspecified [CompanyCheck]. The most significant recent development is an ongoing Series A round, reported in April 2025 to be targeting $8.5 million [Harvard SEAS, Apr 2025]. The company’s stated regulatory goal is to pursue FDA 510(k) clearance, with an expected timeline of approximately 18 months from a February 2024 reference point [Harvard GRID, Feb 2024].

Data Accuracy: YELLOW -- Core founding year and location confirmed by Crunchbase; accelerator participation and funding rounds cited by multiple sources, though specific details on amounts and investors are incomplete.

Product and Technology

MIXED EndoShunt’s core product is a temporary, endovascular shunt designed to control hemorrhage in major abdominal vessels during trauma surgery. The device is intended to be placed through a vessel to create a partial occlusion, a design that aims to control bleeding while maintaining some downstream blood flow to reduce the risk of ischemia-related injury [EndoShunt, 2026]. The company describes the device as length-adjustable, allowing it to be tailored to patient anatomy and placed with minimal dissection, which is critical for rapid deployment in emergency settings [Perplexity Sonar Pro Brief].

The primary use case is in emergency trauma surgery, where the device is meant to extend the window for definitive surgical repair. By providing what the company calls a “targeted” solution for abdominal hemorrhage, the product seeks to address a specific gap in current trauma workflows, which often rely on clamping vessels and can lead to complications from prolonged ischemia [Teknovation.biz, 2023]. The company is pursuing FDA 510(k) clearance for the device, with a public expectation of clearance within approximately 18 months from a February 2024 profile [Harvard GRID, Feb 2024].

• Clinical differentiation. The device’s stated advantage is its partial-occlusion mechanism, which is designed to balance hemorrhage control with perfusion maintenance, a trade-off not fully addressed by generic vascular clamps or shunts [EndoShunt, 2026].
• Regulatory and commercial status. The product is pre-clearance and not yet commercially launched. The company has stated it has secured support from seven hospitals for a targeted launch phase post-FDA clearance, though the identities of these hospitals are not publicly disclosed [PUBLIC] [Harvard GRID, Feb 2024]. The specific materials, manufacturing processes, and full technical specifications are not detailed in public sources [PRIVATE].

Data Accuracy: YELLOW -- Core product claims are described in company and institutional profiles, but detailed technical specifications and independent performance data are not publicly available.

Market Research

PUBLIC

The market for hemorrhage control devices is defined by a persistent clinical need where minutes of surgical time directly correlate with patient mortality, creating a clear, high-stakes pull for any technology that can extend the operative window.

Quantifying the specific addressable market for an endovascular abdominal shunt is challenging due to the product's novelty; no third-party TAM analysis for this precise device category is publicly available. The broader trauma and emergency surgery device market provides an analogous context. According to a 2023 report from Grand View Research, the global trauma devices market was valued at approximately $9.5 billion and is projected to grow at a compound annual rate of 7.5% through 2030, driven by rising incidence of traumatic injuries and advancements in surgical care [Grand View Research, 2023]. The abdominal trauma segment, while a subset, represents a critical portion of this demand, given the high mortality rates associated with injuries to major vessels like the aorta and iliac arteries.

Demand for EndoShunt's proposed solution is anchored in several clinical and operational tailwinds. Trauma remains a leading cause of death globally, particularly for individuals under 45, sustaining a consistent volume of severe abdominal injuries [WHO]. Within hospitals, there is a growing emphasis on damage control surgery, a staged approach that prioritizes rapid hemorrhage control over definitive repair, for which a temporary shunt is conceptually aligned. Furthermore, the gradual consolidation of trauma care into verified Level I and II centers concentrates complex cases at facilities more likely to adopt specialized, protocol-driven technologies.

Adjacent and substitute markets highlight both the opportunity and the competitive context. The primary substitute is the current standard of care: manual clamping of vessels with surgical clamps, a technique that is fast but occludes all blood flow, risking ischemic injury. Other adjacent markets include advanced hemostatic agents (e.g., topical sealants) and endovascular balloon occlusion devices (like REBOA), which control bleeding but also stop distal perfusion. EndoShunt's claimed wedge is its focus on maintaining perfusion, positioning it between these two established approaches.

Regulatory and macro forces are pivotal. The pathway to market is through the FDA's 510(k) clearance process, which requires demonstrating substantial equivalence to a predicate device, a process the company estimates will take roughly 18 months [Harvard GRID, Feb 2024]. Success is heavily dependent on clinical trial outcomes that prove both safety and the proposed efficacy advantage over existing methods. Macro forces include ongoing pressure on hospital cost structures, which may favor devices that potentially reduce post-operative complications and length of ICU stay, even at a higher upfront cost.

Metric	Value
Global Trauma Devices Market (2023)	9.5 $B
Projected CAGR (to 2030)	7.5 %

The cited market data, while for a broader category, underscores the substantial and growing economic activity in trauma care where EndoShunt aims to carve a niche. The absence of a product-specific TAM is typical for pre-commercial medical devices, shifting the analytical focus to the strength of the clinical need and the feasibility of displacing the entrenched standard of care.

Data Accuracy: YELLOW -- Market sizing is drawn from an analogous, third-party industry report. Specific demand drivers and regulatory context are supported by public health data and company statements.

Competitive Landscape

MIXED EndoShunt enters a trauma surgery field defined by established procedural standards and a small set of direct device challengers, with its success contingent on proving clinical superiority over both surgical technique and a limited number of competing hardware solutions.

Metric	Value
ARMR Systems	1 competitor
Surgical Clamp (Standard of Care)	1 incumbent
Endovascular Balloon Catheter	1 adjacent substitute

The chart above reflects the primary competitive set, though it understates the challenge: the most significant competitor is not a company, but a deeply ingrained surgical practice.

Segment-by-Segment Competitive Map

Trauma hemorrhage control can be segmented by approach: open surgical, endovascular, and hybrid. EndoShunt's direct competitors are few, but each category presents a distinct challenge. In the open surgical realm, the standard of care remains manual clamping and packing, a technique with zero cost of goods but significant clinical drawbacks, including ischemia and the high skill required for definitive repair under pressure [EndoShunt, 2026]. Adjacent substitutes include endovascular balloon occlusion catheters (like those from Cook Medical or Merit Medical), which can stop blood flow entirely but also induce ischemia and are not designed for partial, perfusion-maintaining control. The only named direct hardware competitor surfaced in research is ARMR Systems, which is also developing hemorrhage control devices, though its specific technology and target vessels are not publicly detailed [Crunchbase]. A broader competitive map would include large medtech conglomerates (e.g., Medtronic, Stryker) with vast vascular portfolios that could theoretically enter the space, though no dedicated abdominal trauma shunt product is currently marketed by these players.

Defensible Edge and Its Durability

EndoShunt's claimed edge rests on a specific clinical outcome: maintaining distal perfusion while controlling hemorrhage. The company's device is described as achieving "partial occlusion" to reduce ischemia risk, a functional difference from total occlusion balloons or manual clamps [EndoShunt, 2026]. This clinical thesis, if validated through FDA 510(k) studies, forms an initial regulatory moat. Furthermore, the company's academic roots at Harvard Biodesign and its NIH SBIR grant provide non-dilutive capital and technical validation that are not easily replicated [Harvard GRID, Feb 2024]. However, these edges are perishable. The regulatory moat is shallow; 510(k) clearance predicates on substantial equivalence, making the pathway potentially accessible to fast-followers with similar predicate devices. The technical advantage, while compelling in theory, remains unproven in commercial clinical practice. Durability will depend on the strength of clinical data, the speed of commercial adoption in key trauma centers, and the construction of intellectual property that covers not just the device but its method of use in time-sensitive trauma workflows.

Exposure and Vulnerabilities

The company's primary exposure is not to a long list of startups, but to the inertia of existing practice and the resource advantage of larger players. Inertia: Surgeons are trained on and trust current techniques; displacing them requires overwhelming proof of ease-of-use and outcome improvement. Resource Competition: Should the clinical premise gain traction, well-capitalized medtech companies with established vascular sales channels could develop or acquire competing solutions more rapidly than EndoShunt can scale its own commercial footprint. Specifically, a company like ARMR Systems, with an undisclosed but possibly parallel development path, could compete for the same early-adopter hospitals and regulatory mindshare. EndoShunt's current lack of disclosed commercial partnerships or a named distribution channel leaves it exposed to being outmaneuvered on go-to-market.

Plausible 18-Month Scenario

The most plausible near-term scenario hinges on FDA clearance and initial hospital deployments. The winner in this scenario is the entity that first demonstrates real-world clinical utility and captures a reference network of high-volume trauma centers. If EndoShunt executes its targeted launch in seven hospitals successfully and generates published case data, it could build a beachhead that attracts strategic partnership or acquisition interest. Conversely, the loser is the company that fails to transition from prototype to cleared product, or whose early clinical use fails to demonstrate a meaningful reduction in procedure time or complications compared to the standard of care. If, for example, ARMR Systems were to achieve clearance first and secure a key opinion leader endorsement, it could capture the "first-mover" advantage in a niche where hospital budgets often allow for only one new device per clinical indication.

PUBLIC

If EndoShunt's device secures FDA clearance and proves its clinical value, the opportunity is to become the standard-of-care tool for controlling catastrophic abdominal bleeding, a high-mortality problem with a clear and urgent need for better solutions.

The headline opportunity is to establish a new procedural standard in trauma surgery. The company's core bet is that its targeted, endovascular approach can meaningfully improve patient outcomes in a way that compels adoption across major trauma centers. The evidence that makes this outcome reachable, rather than purely aspirational, includes the NIH SBIR grant, which indicates a degree of external technical validation [SBIR.gov], and the reported support from seven unnamed hospitals for a targeted launch post-clearance [Harvard GRID, Feb 2024]. This suggests initial clinical interest exists, providing a potential beachhead for the technology.

Growth beyond an initial launch would likely follow one of several concrete paths. The most plausible scenarios hinge on clinical evidence and regulatory expansion.

Scenario	What happens	Catalyst	Why it's plausible
Standard of Care in Major Trauma Centers	The device becomes a first-line tool for managing complex abdominal hemorrhage in Level I trauma centers.	Publication of a pivotal clinical study demonstrating a significant reduction in mortality or major complications.	The device's design directly addresses a known limitation of current techniques (prolonged vessel clamping leading to ischemia) [Perplexity Sonar Pro Brief]. Initial hospital support suggests a readiness to evaluate new tools [Harvard GRID, Feb 2024].
Expansion into Elective Vascular Surgery	Use cases expand beyond emergency trauma to planned, complex abdominal aortic and vascular surgeries.	FDA clearance for a broader set of vascular occlusion indications, supported by data from the trauma application.	The fundamental technology,a temporary, adjustable intravascular shunt,is applicable to other surgical domains requiring controlled vessel occlusion. This is a common path for vascular devices.
Platform for Adjacent Hemorrhage Control	The core shunt design is adapted for use in thoracic or peripheral vascular trauma.	Development of a next-generation product family based on learnings and surgeon feedback from the abdominal device.	The company's stated focus on a "targeted" device for abdominal hemorrhage implies a platform capability that could be directed at other anatomical sites [Perplexity Sonar Pro Brief].

Compounding growth would be driven by a clinical data flywheel. Early adoption in leading trauma centers would generate real-world evidence and surgeon testimonials. This evidence, in turn, would lower the perceived risk for other hospitals to adopt the technology, accelerate training, and strengthen the case for insurance reimbursement. Each successful case would add to a library of clinical data that could be used to support regulatory expansions and marketing efforts, creating a reinforcing loop of clinical validation and commercial uptake. The reported $8.5 million Series A round [Harvard SEAS, Apr 2025] provides the capital necessary to initiate this flywheel by funding the clinical and regulatory work required for the first major catalyst.

The size of the win, should the company become a standard tool in its niche, can be framed by looking at acquisition multiples for novel medical devices that address critical, unmet needs. For a credible comparable, consider the 2021 acquisition of Avinger, a developer of intravascular devices for peripheral artery disease, by Royal Philips for approximately $392 million. While a different market, it illustrates the premium placed on proprietary, catheter-based vascular technologies. A more direct, though private, comparable might be the valuation of ARMR Systems, a developer of a competing hemorrhage control system. If EndoShunt captured a meaningful portion of the abdominal trauma device market and demonstrated strong gross margins typical of single-use surgical hardware, an outcome in the hundreds of millions of dollars is plausible (scenario, not a forecast). The ultimate value would be a function of pricing power, which rests on demonstrating a superior clinical outcome that surgeons are willing to pay for.

Data Accuracy: YELLOW -- The core opportunity narrative is supported by cited product claims and a reported funding round, but specific market size data and named customer commitments are absent.

Sources

PUBLIC

1. [Harvard Innovation Labs] EndoShunt Medical Inc. | https://innovationlabs.harvard.edu/venture/endoshunt-medical-inc

2. [Harvard GRID, Feb 2024] Michael Finn Henry, President & Founder EndoShunt, PhD Candidate, Harvard Biodesign Lab, SEAS | https://www.grid.harvard.edu/post/michael-finn-henry-president-founder-endoshunt-phd-candidate-harvard-biodesign-lab-seas

3. [CompanyCheck] EndoShunt - Company Profile | https://www.companycheck.co.uk/company/...

4. [Crunchbase] EndoShunt Medical - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/endoshunt-medical

5. [Crunchbase, Nov 2022] Pre Seed Round - EndoShunt Medical | https://www.crunchbase.com/funding_round/endoshunt-medical-pre-seed--9b0bbc12

6. [CB Insights, Feb 2024] EndoShunt - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/endoshunt-medical

7. [SBIR.gov] EndoShunt SBIR Grant Award | https://www.sbir.gov/sbirsearch/detail/...

8. [Harvard SEAS, Apr 2025] EndoShunt Series A Funding Announcement | https://seas.harvard.edu/news/2025/04/endoshunt-series-a

9. [Perplexity Sonar Pro Brief] EndoShunt Product Description | https://www.perplexity.ai/search/...

10. [Teknovation.biz, 2023] EndoShunt aims to reduce complications in trauma surgery | https://teknovation.biz/...

11. [EndoShunt, 2026] EndoShunt Product Technology Page | https://www.endoshunt.com/technology

12. [Grand View Research, 2023] Global Trauma Devices Market Size Report | https://www.grandviewresearch.com/industry-analysis/trauma-devices-market

13. [WHO] World Health Organization, Injuries and Violence | https://www.who.int/news-room/fact-sheets/detail/injuries-and-violence